A brief introduction to BV-2
Summary
BV-2 shares properties with body macrophages with respect to the antigen profile, their phagocytic capacity and antimicrobial activity. BV-2 is widely used as an alternative model system for primary microglia and neurodegenerative disease model in vitro. The model is usually induced by Lipopolysaccharide (LPS) treatment.- Author Name: AcceGen
BV-2 Cells Derivation and biomarker
BV-2 is a type of microglial cell derived from C57/BL6 murine. The BV2 cells are immortalized by v-raf /v-myc carrying J2 retrovirus. BV2 express nuclear v-myc and the cytoplasmic v-raf oncogene products as well as the env gp70 antigen at the surface level. BV2 microglia cell line retains microglia morphological and functional characteristics. In accordance with v-raf/v-myc expressed characters, the metabolic and proliferation rate of in vitro BV-2 greatly exceeds that of other microglia.
BV-2 Cells Application and example model
In the central nervous systems (CNS), microglial cells are resident macrophages. BV-2 shares properties with body macrophages with respect to the antigen profile, their phagocytic capacity and antimicrobial activity. Like other microglia, BV-2 can be activated to release pro-inflammatory cytokines by oxidative stress or inflammatory factors. Such stimulus possibly triggers neurodegenerative disorder such as Alzheimer and Parkinson disease, thus BV-2 is widely used as an alternative model system for primary microglia and neurodegenerative disease model in vitro. The model is usually induced by Lipopolysaccharide (LPS) treatment.
Why Choose BV-2 from AcceGen?
AcceGen BV-2 cells are positive for MAC1 and MAC2 antigens, negative for MAC3, glial fibrillary acidic protein (GFAP) and galactocerebroside (GC).
Key Features
-Backed by AcceGen advanced technology
-Cryopreserved for highest viability and plating efficiency
-Quality-tested for accurate results
